Comprehensive cancer genomic profiling in solid tumor patients before completion of standard therapy

Prospective study on comprehensive cancer genomic profiling in solid tumor patients before completion of standard therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1062260005

Enrollment

Registered

2026-06-17

Start date

2026-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors Solid tumors before completion of standard therapy

Interventions

CGP testing using tumor tissue and or peripheral blood samples is performed in patients with solid tumors before completion of standard therapy including those expected to complete standard therapy, a

Comprehensive cancer genomic profiling test

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically proven solid tumor 2) Advanced or recurrent stage eligible for systemic chemotherapy 3) The CGP test covered by insurance has not yet been performed 4) The attending physician must determine that the current CGP test is not covered by insurance at the time of study enrollment 5) Samples can be submitted suitable for genetic analysis (at least one of items 1 or 2). 1. Post-treatment residual tumor tissue sample 2. Peripheral blood samples collected specifically for this study 6) The patient consented to registering their information with the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) and using their data 7) Written consent for partcipation in this study must be obtained from the patient (for patients under 18 years of age, consent from a legal representative is required inaddition to the patient's consent). However, even if the patient understands the information provided and wishes to give consent, but is unable to sign due to neurological symptoms or other reasons, and the patient so desires, a proxy may sign on the patient's behalf to confirm consent.

Exclusion criteria

Exclusion criteria: 1) Patients who have already participated in this study and have previously undergone CGP testing under the framework of Advanced Medical Care A.

Design outcomes

Primary

Measure	Time frame
The proportion of patients who receive molecularly targeted therapy corresponding to actionable genomic alterations identified by the CGP testing performed in this study, including standard-of-care treatments prescribed based on approved companion diagnostics.	—

Secondary

Measure	Time frame
-The proportion of patients for whom molecularly targeted therapy is recommended based on actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients enrolled in clinical trials evaluating molecularly targeted therapies corresponding to actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients in whom diagnostically informative genomic alterations are identified by the CGP test performed in this study. -Overall survival	—

Measure

Time frame

-The proportion of patients for whom molecularly targeted therapy is recommended based on actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients enrolled in clinical trials evaluating molecularly targeted therapies corresponding to actionable genomic alterations identified by the CGP testing performed in this study. -The proportion of patients in whom diagnostically informative genomic alterations are identified by the CGP test performed in this study. -Overall survival

—

Contacts

Public ContactHiromasa Yamamoto

Shimane University Hospital

h.yamamoto@med.shimane-u.ac.jp+81-853-88-3053

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026